Switching HIV treatment regimens during the first trimester; drivers of viral breakthrough during pregnancy; HIV’s effect on liver risk after hepatitis C treatment; hepatic steatosis among young people with HIV.
A Canadian study of this cost-saving approach found high acceptance of de-simplification among people already on a single-tablet regimen, and even higher rates among people who were just initiating single-tablet treatment.
The most popular form of long-acting HIV treatment; telehealth for PrEP uptake among young MSM of color; PrEP awareness and usage among Rhode Island women; assessing cognitive benefits of switching off of efavirenz.
A recent case study illustrates the complexity of managing women in early stages of pregnancy presenting on a dolutegravir-based regimen, and the need for careful consideration when responding to new data.
Given the potency of new antiretroviral therapy (ART) and the life-long duration that people living with HIV/AIDS will require ART, there is a continued interest in two-drug ART regimens.
Reports about bictegravir, the most recently approved integrase inhibitor, were included in an oral presentation and in several posters at CROI 2018.
During a clinical trial of the broadly neutralizing antibody VRC01, study results offered reassurance that treatment interruption had no long-term negative effects for participants -- but there are some possible safety concerns that the data does not...
The findings may aid the design of clinical trials to assess strategies to control HIV without drugs.
A major trial is currently underway that may confirm that patients could omit several days of treatment a week without risk to their health.
Deciding what to do after the failure of a first-line regimen has long entailed a bit of head-scratching. Aside from the investigation into what went wrong (e.g., adherence), there is the matter of selecting a salvage regimen that can suppress virus ...